Notice for tafamidis and tafamidis meglumine (Pfizer Australia Pty Ltd)
Active ingredients
tafamidis and tafamidis meglumine
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Capsule, soft
Indication
For the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) due to wild type or variant transthyretin.